| Writing group member | Employment | Research grant | Other research support | Speakers’ bureau/honoraria | Expert witness | Ownership interest | Consultant/advisory board | Other |
|---|---|---|---|---|---|---|---|---|
| Vanessa Blumer | Inova Schar Heart and Vascular | None | None | None | None | None | None | None |
| Manreet Kanwar | Cardiovascular Institute at Allegheny Health Network | Cardiogenic Shock Working Group (Steering Committee member)* | None | Abiomed† | None | None | Abiomed†; CorWave (unpaid)*; Abbott* | None |
| Christopher Barnett | University of California San Francisco | None | None | None | None | None | None | None |
| Jennifer A. Cowger | Henry Ford Hospital | None | None | Zoll*; Bioventrix*; Abbott* | None | Procyrion* | Abbott†; Nuwellis (unpaid)*; Endotronix (unpaid)*; Bivacor (unpaid)*; Medtronic* | None |
| Abdulla A. Damluji | Johns Hopkins University Inova Center of Outcomes Research | None | None | None | None | None | None | None |
| Maryjane Farr | The University of Texas Southwestern Medical Center | None | None | None | None | None | None | None |
| Sarah J. Goodlin | Oregon Health and Sciences University, Patient-Centered Education and Research | None | None | None | None | None | None | None |
| Jason N. Katz | NYU Grossman School of Medicine & Bellevue Hospital Center | Abbott Corp* | None | None | None | None | None | None |
| Colleen K. McIlvennan | University of Colorado Cardiology | None | None | None | None | None | None | University of Colorado (associate professor)† |
| Shashank S. Sinha | Inova Schar Heart and Vascular, Inova Fairfax Medical Campus | None | None | None | None | None | None | None |
| Tracy Y. Wang | Duke Clinical Research Institute | None | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $5000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $5000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.